Genome Editing and Chimeric Antigen Receptors T Cell Therapy
Hassan, R. (2017). Genome Editing and Chimeric Antigen Receptors T Cell Therapy. EKB Journal Management System, 20(2), 122-127. doi: 10.21608/scumj.2017.43560
Ranya Hassan. "Genome Editing and Chimeric Antigen Receptors T Cell Therapy". EKB Journal Management System, 20, 2, 2017, 122-127. doi: 10.21608/scumj.2017.43560
Hassan, R. (2017). 'Genome Editing and Chimeric Antigen Receptors T Cell Therapy', EKB Journal Management System, 20(2), pp. 122-127. doi: 10.21608/scumj.2017.43560
Hassan, R. Genome Editing and Chimeric Antigen Receptors T Cell Therapy. EKB Journal Management System, 2017; 20(2): 122-127. doi: 10.21608/scumj.2017.43560

Genome Editing and Chimeric Antigen Receptors T Cell Therapy

Suez Canal University Medical Journal
Editorial, Volume 20, Issue 2, October 2017, Page 122-127  XML PDF (819.83 K)
DOI: 10.21608/scumj.2017.43560
View on SCiNiTO View on SCiNiTO
Author
Ranya Hassan email
Clinical pathology Department, Faculty of Medicine, Suez Canal university, Egypt
Abstract
Recent advances in genome editing technologies have significantly enhanced making specific changes in the genomes of different types cells. Genetically engineered T cells, or the 'living drugs', is considered a new era in antitumor therapy. Current clinical trials using chimeric antigen receptors (CARs) T cells showed a promising result in patients with some intractable hematological malignancies. In this Review, some of the most recent advances in CAR T cell therapy are mentioned high lightening the use of genome editing in this field.
Keywords
CRISPR/Cas9; chimeric antigen receptor; T lymphocytes; gene therapy
Statistics
Article View: 178
PDF Download: 326